![Covaxin Phase-3 Clinical Trials Begin in AIIMS
Covaxin Phase-3 Clinical Trials Begin in AIIMS](https://images.medindia.net/health-images/1200_1000/effective-vaccine-alone-can-end-the-pandemic.jpg)
‘Covaxin, India's indigenous coronavirus vaccine by Bharat Biotech, is developed in collaboration with the ICMR - National Institute of Virology (NIV).
’
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
Bharat Biotech announced the commencement of Phase-3 trials of Covaxin on November 16. The Phase-3 trials will involve 26,000 participants across India, conducted in partnership with ICMR. ![twitter](https://images.medindia.net/icons/news/social/twitter.png)
![facebook](https://images.medindia.net/icons/news/social/facebook.png)
![linkedin](https://images.medindia.net/icons/news/social/linkedin.png)
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
It is the biggest clinical trial conducted for a coronavirus vaccine in India.
Trial volunteers will take two intramuscular injections approximately 28 days apart. Participants will be randomly assigned to get Covaxin or placebo. The trial is double-blinded, where the investigators, the participants, and the company will not be aware of who is assigned to which group.
Covaxin has been evaluated in 1,000 subjects in Phase-1 and Phase-2 clinical trials, promising safety and immunogenicity data. Volunteers who wish to join in this trial should be adults over 18 years of age.
Advertisement